title: Phosphorylation-independent effects of second messenger system modulators on gamma-aminobutyric acidA receptor complex function.
abstract: Recent studies investigating the functional significance of gamma-aminobutyric acidA (GABAA) receptor complex phosphorylation have employed membrane-permeant compounds to manipulate second messenger systems. Although these compounds affect GABAA receptor function, the dependence of these effects on phosphorylation has not been established. Here we report that several second messenger system modulations can decrease GABAA receptor function independently of their effects on protein phosphorylation. Brain membrane vesicles were lysed and resealed in the presence of EDTA to chelate internal Mg2+. Under these conditions, phosphorylation of vesicle proteins was almost completely inhibited, as determined by incorporation of 32P into phosphoproteins. In these lysed/resealed vesicles, an inhibition of muscimol-stimulated 36Cl- uptake was observed with the cAMP analogs 8-(4-chlorophenylthio)-cAMP, N6,O2'-dibutyryl-cAMP, and 8-bromo-cAMP, the protein kinase inhibitor H7, and the adenylate cyclase activator forskolin. In both intact and EDTA-treated lysed/resealed microsacs, cAMP analogs and H7 inhibited binding of the GABAA receptor ligand [3H]SR 95531 at concentrations shown to inhibit muscimol-stimulated 36Cl- uptake. Forskolin was observed to inhibit the binding of t-butylbicyclophosphoro-[35S]thionate, a ligand that binds to a site on the chloride channel. These results demonstrate that compounds commonly used to alter second messenger systems affect the receptor sites and function of the GABAA receptor chloride channel by mechanisms that do not involve protein phosphorylation. In light of these findings, results obtained with these compounds should be interpreted with caution.
authors.affiliation: Denver Veterans Administration Medical Center, Colorado.
authors.forename: N J
authors.initials: NJ
authors.lastname: Leidenheimer
authors.forename: M D
authors.initials: MD
authors.lastname: Browning
authors.forename: T V
authors.initials: TV
authors.lastname: Dunwiddie
authors.forename: L D
authors.initials: LD
authors.lastname: Hahner
authors.forename: R A
authors.initials: RA
authors.lastname: Harris
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000818:Animals; D002712:Chlorides / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology*; D004492:Edetic Acid / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D051379:Mice; D008813:Mice, Inbred ICR; D009118:Muscimol / Q000494:pharmacology; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D011494:Protein Kinases / Q000502:physiology; D011724:Pyridazines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000502:physiology; D015290:Second Messenger Systems / Q000187:drug effects*
chemical_list: D002712:Chlorides; D007546:Isoquinolines; D010879:Piperazines; D011724:Pyridazines; D011963:Receptors, GABA-A; D005576:Colforsin; D009118:Muscimol; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; C053177:N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide; C049853:gabazine; D004492:Edetic Acid; D000242:Cyclic AMP; D011494:Protein Kinases